Algallio Biotech Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 9 Year, 26 Days
- Last Filing with ROC 31 Mar 2020
- Revenue Growth -28.66%
- Profit Growth 21.69%
- Ebitda 26.53%
- Net Worth -26.02%
- Total Assets -9.70%
About Algallio Biotech
Algallio Biotech Private Limited (ABPL) is a Private Limited Indian Non-Government Company incorporated in India on 13 January 2016 (Nine years 26 days old ). Its registered office is in Vadodara, Gujarat, India.
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Sanjiv Mishra, Chetan Paliwal, Shrivastava Vijaykumar, and Three other members serve as directors at the Company.
Company Details
-
Location
Vadodara, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U74140GJ2016PTC085719
-
Company No.
085719
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
13 Jan 2016
-
Date of AGM
31 Dec 2020
-
Date of Balance Sheet
31 Mar 2020
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Algallio Biotech?
Board Members (6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjiv Mishra
|
Director | 13-Jan-2016 | Current |
|
Chetan Paliwal
|
Director | 13-Jan-2016 | Current |
|
Shrivastava Vijaykumar
|
Director | 13-Jan-2016 | Current |
|
Amee Patel
|
Director | 13-Jan-2016 | Current |
|
Manan Amin
|
Director | 04-Nov-2017 | Current |
|
Savita Gangwar
|
Director | 04-Nov-2017 | Current |
Financial Performance of Algallio Biotech.
Algallio Biotech Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 28.66% decrease. The company also saw a substantial improvement in profitability, with a 21.69% increase in profit. The company's net worth observed a substantial decline by a decrease of 26.02%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Algallio Biotech?
In 2020, Algallio Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Dr. Neutrology Private LimitedSanjiv Mishra is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Algallio Biotech?
Unlock and access historical data on people associated with Algallio Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Algallio Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Algallio Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.